3-methyl-4-(trifluoromethyl )-1H-benzimidazol-2-one | 1150102-43-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-methyl-4-(trifluoromethyl )-1H-benzimidazol-2-one
• 英文别名: 1-Methyl-7-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one；3-methyl-4-(trifluoromethyl)-1H-benzimidazol-2-one
• CAS: 1150102-43-4
• 化学式: C₉H₇F₃N₂O
• 分子量: 216.163
• InChiKey: ICNSYWUAUIUVSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] PARG INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE PARG
  申请人：CANCER REC TECH LTD

  公开号：WO2016097749A1

  公开（公告）日：2016-06-23

  The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

  本发明涉及作为PARG（Poly ADP-ribose glycohydrolase）酶活性抑制剂的化合物I的公式，其中R1a、R1b、R1c、R1d、R1e、W、X1、X2、X3、X4、X5、X6、X7、c分别如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及PARG活性的疾病或症状中的用途。
• PARG inhibitory compounds
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US10995073B2

  公开（公告）日：2021-05-04

  The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

  本发明涉及作为PARG（聚ADP-核糖糖水解酶）酶活性抑制剂的式I化合物：其中R1a、R1b、R1c、R1d、R1e、W、X1、X2、X3、X4、X5、X6、X7、c各自如本文所定义。本发明还涉及这些化合物的制备工艺、包含这些化合物的药物组合物，以及它们在治疗增殖性疾病（如癌症）和其他涉及 PARG 活性的疾病或病症中的用途。
• PARG INHIBITORY COMPOUNDS
  申请人：Cancer Research Technology Limited

  公开号：EP3233845A1

  公开（公告）日：2017-10-25
• Thiazole Derivatives as Protein Kinase Inhibitors
  申请人：Reddy Panduranga Adulla P.

  公开号：US20100331313A1

  公开（公告）日：2010-12-30

  The present invention relates to novel Thiazole Derivatives, compositions comprising the Thiazole Derivatives, and methods for using the Thiazole Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase.
• US8476278B2
  申请人：——

  公开号：US8476278B2

  公开（公告）日：2013-07-02